乳腺癌是全球第二大高发癌症,也是全球女性中最常见的癌症。据统计,2022年中国乳腺癌新发病例数约为35.7万例,死亡病例数约为7.5万例,其中,约20%的病例在确诊时已处于晚期或转移性阶段。虽然早期乳腺癌患者的生存率较高,但在转移性乳腺癌患者中,预计5年生存率仅为约30%。2026年2月11日,据中国国家药品审评中心(CDE)官网显示,石药集团中奇制药技术(石家庄)有限公司按注册分类2.4类申报的...
Source Link乳腺癌是全球第二大高发癌症,也是全球女性中最常见的癌症。据统计,2022年中国乳腺癌新发病例数约为35.7万例,死亡病例数约为7.5万例,其中,约20%的病例在确诊时已处于晚期或转移性阶段。虽然早期乳腺癌患者的生存率较高,但在转移性乳腺癌患者中,预计5年生存率仅为约30%。2026年2月11日,据中国国家药品审评中心(CDE)官网显示,石药集团中奇制药技术(石家庄)有限公司按注册分类2.4类申报的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.